Evidence map›Paper›PMID 26798176›Full record

ArticleIndian journal of pharmaceutical sciences

Development and Validation of Stability-indicating High Performance Liquid Chromatographic Method for the Estimation of Everolimus in Tablets.

D Sharmila, A Lakshmana Rao, L Kalyani

Abstract read
In one paragraph

Article in Indian journal of pharmaceutical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning.Angewandte Chemie (International ed. in English) · 2024
    Article
  2. Article
  3. Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

D SharmilaVallabhaneni Venkatadri Institute of Pharmaceutical Sciences, Seshadri Rao Knowledge, Krishna, Gudlavalleru-521 356, India.
A Lakshmana RaoVallabhaneni Venkatadri Institute of Pharmaceutical Sciences, Seshadri Rao Knowledge, Krishna, Gudlavalleru-521 356, India.
L KalyaniVallabhaneni Venkatadri Institute of Pharmaceutical Sciences, Seshadri Rao Knowledge, Krishna, Gudlavalleru-521 356, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study depicts the development of a validated reversed-phase high performance liquid chromatographic method for the determination of the everolimus in presence of degradation products or pharmaceutical excipients. Stress study was performed on everolimus and it was found that it degrade sufficiently in oxidizing and acidic conditions but less degradation was found in alkaline, neutral, thermal and photolytic conditions. The separation was carried out on Hypersil BDS C18 column (100×4.6 mm, 5 μ) column having particle size 5 μ using acetate buffer:acetonitrile (50:50 v/v) with pH 6.5 adjusted with orthophosphoric acid as mobile phase at flow rate of 1 ml/min. The wavelength of the detection was 280 nm. A retention time (Rt) nearly 3.110 min was observed. The calibration curve for everolimus was linear (r(2)=0.999) from range of 25-150 μg/ml with limit of detection and limit of quantification of 0.036 μg/ml and 0.109 μg/ml, respectively. Analytical validation parameters such as selectivity, specificity, linearity, accuracy and precision were evaluated and relative standard deviation value for all the key parameters were less than 2.0%. The recovery of the drug after standard addition was found to be 100.55%. Thus, the developed RP-HPLC method was found to be suitable for the determination of everolimus in tablets containing various excipients.

Indexed as

Everolimusreversed-phase high performance liquid chromatographicstabilityvalidation

Identifiers

PMID26798176
PMCPMC4700714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.